share_log

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91

Chardan Capital维持对intellia therapeutics的买入评级,将目标价格提高至91美元
Benzinga ·  11/18 10:23  · 评级/大行评级

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $88 to $91.

Chardan Capital 分析师Geulah Livshits维持intellia therapeutics(纳斯达克:NTLA)的买入评级,并将目标股价从88美元上调至91美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发